Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab

Background: RNA splicing factor (SF) mutations are associated with adverse outcomes in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes/neoplasms (HR-MDS). Preclinical data suggest that aberrant RNA splicing can lead to the generation of neoantigens, which renders...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac Boss, Lourdes Mendez, Nikolai Podoltsev, Maximilian Stahl, Tariq Kewan, Stephanie Halene, Torsten Haferlach, Brian A. Fox, Amer M. Zeidan
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	SAGE Publishing 2025-06-01
Reeks:	Therapeutic Advances in Hematology
Online toegang:	https://doi.org/10.1177/20406207251347344
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!